Humacyte Human Acellular Vessel™ (HAV™) Ukraine Humanitarian Results to be Presented at Multiple Vascular Conferences in December 2022
DURHAM, N.C., Dec. 01, 2022 (GLOBE NEWSWIRE) -- Humacyte, Inc. (Nasdaq: HUMA), a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissues and advanced tissue constructs and organ systems at commercial scale, today announced presentations on the Company’s Human Acellular Vessel (HAV) by Ukrainian surgeon collaborators, Oleksandr Sokolov, M.D., Ph.D., Vasyl Shaprynskyi, M.D., Ph.D., and Oleksandr Stanko, M.D, at the VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine taking place in Kyiv, Ukraine from December 1-3, 2022. In addition, Ukrainian surgeon collaborator, Dr. Sokolov, will present on Humacyte’s HAV at the 11th Munich Vascular Conference (MAC) 2022, taking place virtually from December 2-3, 2022. Details of the conferences are as follows:
VI Congress of Vascular Surgeons, Phlebologists, and Angiologists of Ukraine
Presentation Title: Early Diagnosis and Treatment of Arteriovenous Fistulas as a Result of Explosive Vascular Injuries
Presentation Title: The First Experience of Using the Human Acellular Vessels (HAV) in Ukraine for the Treatment of Patients with Vascular Trauma
11th Munich Vascular Conference (MAC) 2022
Presentation Title: Vascular Trauma in Ukrainian War Survivors
The HAV results included in these presentations are part of Humacyte’s humanitarian relief initiative to provide investigational HAVs to multiple front-line Ukrainian hospitals for the treatment of patients with traumatic vascular injuries sustained during the conflict in Ukraine. Humacyte is currently evaluating te HAV in a Phase 2/3 clinical trial in vascular trauma for use as a vascular replacement to restore blood flow to a limb, when saphenous veins or alternate synthetic grafts are not a good option or not available. The HAV is an investigational product and has not been approved for sale by the FDA, the Ukrainian Ministry of Health, or any international regulatory agency.
Humacyte Media Contact:
Welcome Reception - For Diamond, Platinum, Super Pass, Exhibitor/Conference, Speaker, Press Pass Holders
Are You Really Getting the Most from Your Technology to Support Todayâ€™s Workforce?
IoT Evolution Expo #TECHSUPERSHOW Expo Hall Grand Opening